TLR4 agonists and compositions thereof and their use in the treatment of cancer
US10765690B2 · kind B2 · utility
1Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 3, 2016 |
| Grant date | Sep 8, 2020 |
| Priority date | — |
| Expiry date | Jun 22, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a TLR4 agonist alone or in combination with an anti-cancer agent and pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said composition or combination, including uses in cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.